Please use this identifier to cite or link to this item:
Title: Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era
Austin Authors: Jalali, Azim;Ha, Francis J;Chong, Geoff;Grigg, Andrew P ;Mckendrick, Joe;Schwarer, Anthony P ;Doig, Rowan;Hamid, Anis;Hawkes, Eliza A 
Affiliation: Eastern Health, Monash University Clinical School, Melbourne, Victoria, Australia
Department of Oncology and Clinical Haematology, Olivia Newton-John Cancer & Wellness Centre, Austin Health, Heidelberg, Victoria, Australia
Department of Oncology, Northern Hospital, Melbourne, Victoria, Australia
Issue Date: Apr-2016
Date: 2016-04
Publication information: Annals of Hematology 2016; 95(5): 809-816
Abstract: Approximately 560 new cases of Hodgkin lymphoma (HL) are diagnosed annually in Australia. Standard first-line therapy is ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine). It is unknown how survival outcomes in patients receiving ABVD in current clinical practice, with routine positron emission tomography (PET) imaging and modern supportive measures, compare with results from published trials. This is a retrospective multi-centre study of patients with previously untreated HL between November 1999 and December 2014 receiving ABVD induction. Baseline characteristics, treatment details, toxicity and outcome data were collected from hospital records. The primary endpoint was overall survival (OS). Secondary endpoints included overall response rate (ORR), progression-free survival (PFS), response to treatment and toxicity. One hundred and eighty-nine eligible patients were identified. Median age was 32 years (range 17-79). Nodular-sclerosing HL was the most common subtype (78 %), 44 % had B symptoms and 11 % had marrow involvement. Median number of cycles of ABVD administered was 6 (range 3-8). Eighteen patients (11 %) had dose delay, 21 (13 %) had dose reductions and 11 (8 %) had both. The ORR, defined predominantly by PET scan, was 96 % (CR 89 %). Five-year OS and PFS were 93 and 84 %, respectively in early disease (stage I-IIA) and 89 and 63 % in advanced disease (stage IIB, III and IV). No poor prognostic factors were identified on multivariate testing. The most common grade 3/4 toxicity was neutropenia (53 %). Our study confirms the excellent prognosis and manageable toxicity in HL patients receiving ABVD in phase III studies are reflected in patients treated in routine clinical practice in the modern era.
DOI: 10.1007/s00277-016-2611
PubMed URL:
Type: Journal Article
Subjects: ABVD
Hodgkin lymphoma
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Jul 19, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.